Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr....
GB Sciences, Inc. (OTCQB: GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production...
GB Sciences, Inc. (OTCQB: GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who...
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. This edition (https://mjbizmagazine.com/digital-issues/2019-09-Oct/) examines the evolution ...
GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus...
GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA...
GB Sciences, Inc. (OTCQB: GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager,...
GB Sciences, Inc. (OTCQB: GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the...
GB Sciences Louisiana (OTCQB: GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified...
GB Sciences, Inc. (OTCQB: GBLX), through its subsidiary, GBS Global Biopharma, Inc. ("GBS", Ottawa, CANADA), has filed a novel patent application to protect proprietary formulations for chronic pain...
GB Sciences, Inc. (OTCQB:GBLX) today announced it has obtained an exclusive license to formulate, manufacture, and sell cannabis-infused oral thin films through its MME-licensed subsidiaries and...
GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in...
GB Sciences, Inc. (OTCQB: GBLX) today launched a global expansion strategy with the formation of GBS Global Biopharma Inc. ("GBS Global"), a cannabinoid medicine company based in Canada. GBS Global...
GB Sciences, Inc. (OTCQB: GBLX) announced the harvest of the first test cannabis crop in the company's nationally-recognized collaboration with Louisiana State University Agricultural Center. On...
GB Sciences, Inc. (OTCQB: GBLX) announces that their first crop in the rapidly expanding hemp market expects to yield a gross profit of $0.7million dollars as well as seeds and genetics. These seeds...
GB Sciences, Inc. (OTCQB: GBLX) announced today that Dr. Andrea Small-Howard, Chief Science Officer and GB Sciences' Board Member, will present "Unique Methods to Identify Strong Lead Compounds" at...
GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State...
GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the ...
GB Sciences, Inc. (OTCQB: GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the...
GB Sciences, Inc. (OTCQB: GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma. This company has been awarded cultivation, processing and dispensary ...
GB Sciences, Inc. (OTCQB: GBLX) announces sponsorship of a one day, November 9th, international medical cannabis symposium, "Innovation in Medical Cannabis Therapies", under the direction of Dr....
GB Sciences, Inc. (OTCQB: GBLX) announces that CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard will be featured on panels at the Digital Hollywood's California Cannabis Forum at the...
GB Sciences, Inc. (OTCQB: GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' ...
GB Sciences, Inc. (OTCQB: GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece. Titled: The...
GB Sciences, Inc. (OTCQB: GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)'s decision to reschedule GW Pharmaceuticals' Epidiolex,...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.